Abstract: The disclosed technology provides improved adhesive composition of use with dentures. These improved compositions include (a) a cross linked poly(acrylic) acid polymer, in combination with (b) a carbomethylcellulose (CMC) component and/or (c) an adherence promoting component. The compositions balance the many competing goals for effective denture adhesives, including adhesive strength and dispensing viscosity, without the need for zinc.

Abstract: An amorphous solid dispersion includes a linear poly(acrylic acid) and an active pharmaceutical ingredient. The linear poly(acrylic acid) used to form the amorphous solid dispersion has a Brookfield viscosity of at least 100 cP at 25° C. A method of forming such an amorphous solid dispersion of an active pharmaceutical ingredient includes forming a liquid dispersion of a linear poly(acrylic acid), an active pharmaceutical ingredient, and a solvent system, the linear poly(acrylic acid) having a Brookfield viscosity at 25° C. of at least 100 cP and evaporating the solvent system from the liquid dispersion to form an amorphous solid dispersion.

Abstract: The disclosed technology provides improved adhesive composition of use with dentures. These improved compositions include (a) a cross linked poly(acrylic) acid polymer, in combination with (b) a carbomethylcellulose (CMC) component and/or (c) an adherence promoting component. The compositions balance the many competing goals for effective denture adhesives, including adhesive strength and dispensing viscosity, without the need for zinc.

Abstract: The disclosed technology provides improved drug compositions that provide increased stability, higher drug loading potential, and suitable drug dissolution properties, and methods of making the same. The composition include: (a) a drug component comprising a therapeutically effective amount of a drug; (b) an extended release component comprising a cross-linked polyacrylic acid polymer that is a carbomer homopolymer, carbomer copolymer, carbomer interpolymer, polycarbophil or a mixture thereof; and (c) a buffering component comprising a magnesium containing buffering agent; wherein the drug component makes up at least 50% by weight of the composition.

Abstract: The disclosed technology provides improved drug compositions that provide increased stability, higher drug loading potential, and suitable drug dissolution properties, and methods of making the same. The composition include: (a) a drug component comprising a therapeutically effective amount of a drug; (b) an extended release component comprising a cross-linked polyacrylic acid polymer that is a carbomer homopolymer, carbomer copolymer, carbomer interpolymer, polycarbophil or a mixture thereof; and (c) a buffering component comprising a magnesium containing buffering agent; wherein the drug component makes up at least 50% by weight of the composition.

Abstract: The disclosed technology provides improved adhesive composition of use with dentures. These improved compositions include (a) a cross linked poly(acrylic) acid polymer, in combination with (b) a carbomethylcellulose (CMC) component and/or (c) an adherence promoting component. The compositions balance the many competing goals for effective denture adhesives, including adhesive strength and dispensing viscosity, without the need for zinc.

Abstract: The present invention relates to controlled release drug delivery systems. In one embodiment, the present invention relates to controlled release drug delivery systems comprising a combination of at least one polyacrylic acid and at least one enteric polymer. In another embodiment, the present invention relates to a controlled release pharmaceutical composition comprising the combination of at least one active pharmaceutical ingredient and a controlled release drug delivery system, where the controlled release drug delivery system comprises the combination of at least one polyacrylic acid and at least one enteric polymer.